JP2014514361A5 - - Google Patents

Download PDF

Info

Publication number
JP2014514361A5
JP2014514361A5 JP2014510467A JP2014510467A JP2014514361A5 JP 2014514361 A5 JP2014514361 A5 JP 2014514361A5 JP 2014510467 A JP2014510467 A JP 2014510467A JP 2014510467 A JP2014510467 A JP 2014510467A JP 2014514361 A5 JP2014514361 A5 JP 2014514361A5
Authority
JP
Japan
Prior art keywords
functional food
food composition
composition
composition according
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510467A
Other languages
English (en)
Japanese (ja)
Other versions
JP6027607B2 (ja
JP2014514361A (ja
Filing date
Publication date
Priority claimed from US13/105,470 external-priority patent/US9439875B2/en
Application filed filed Critical
Publication of JP2014514361A publication Critical patent/JP2014514361A/ja
Publication of JP2014514361A5 publication Critical patent/JP2014514361A5/ja
Application granted granted Critical
Publication of JP6027607B2 publication Critical patent/JP6027607B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510467A 2011-05-11 2012-05-10 プテロスチルベンの抗不安効果 Expired - Fee Related JP6027607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 2011-05-11
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202351A Division JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Publications (3)

Publication Number Publication Date
JP2014514361A JP2014514361A (ja) 2014-06-19
JP2014514361A5 true JP2014514361A5 (enExample) 2015-05-28
JP6027607B2 JP6027607B2 (ja) 2016-11-16

Family

ID=47140003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014510467A Expired - Fee Related JP6027607B2 (ja) 2011-05-11 2012-05-10 プテロスチルベンの抗不安効果
JP2016202351A Withdrawn JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202351A Withdrawn JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Country Status (9)

Country Link
US (1) US9439875B2 (enExample)
EP (1) EP2706992B1 (enExample)
JP (2) JP6027607B2 (enExample)
KR (1) KR101929074B1 (enExample)
CN (1) CN103561729B (enExample)
AU (1) AU2012253479B2 (enExample)
BR (1) BR112013028776B1 (enExample)
CA (1) CA2839309C (enExample)
WO (1) WO2012154956A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
WO2018039207A1 (en) * 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057231A1 (en) * 2004-08-19 2006-03-16 Rimando Agnes M Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Jnc株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
EP2445488B1 (en) * 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Similar Documents

Publication Publication Date Title
JP2014514361A5 (enExample)
BR112015014800A2 (pt) derivados da exendina-4 funcionalizada
JP2012144538A5 (enExample)
HUE038313T2 (hu) Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
ZA201003861B (en) Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2012054526A8 (en) Chemosensory receptor ligand-based therapies
CN105263325A8 (zh) 用于降低多发性硬化症中丘脑损伤的拉喹莫德
JP2012136529A5 (enExample)
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
JP2014500291A5 (enExample)
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies
JP2012516348A5 (enExample)
WO2012054530A3 (en) Chemosensory receptor ligand-based therapies
JP2012179231A5 (enExample)
CA2834182C (en) Honey composition with l-alanyl-l-glutamine
François Jacob van Liesvelt Beheaded In Consequence of His 1542 Bible: Legends and Facts
정경희 Policy measures to enhance the quality of life of older persons
Jian-mei et al. Relationship between depression and the factors related to senile patients with hypertension
Selfridge From Padasana to Pain Relief: Iyengar Yoga for Chronic Low Back Pain
Bakalar Patterns: Less Salt Isn’t Always Better for the Heart
TH111315S (th) ถัง
CN302203723S (zh) 男童小便器
CN302291275S (zh) 马桶